RxDoctor Payments DataLook up a doctor →

Gina Berthold, MD

Infectious Disease · Wilmington, NCNPI 1477768182

Payments from drug & device makers

$9,645in general payments, 2019–2025

Across 564 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$2K
  • AbbVie$1K
  • Merck$808
  • Insmed, Inc.$476
  • Novo Nordisk$413
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$9,54099%
  • Education$761%
  • Gifts$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,645 in reported general payments places this provider in the 75th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$89,747
Medicare patients
238
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala84$326,242
DovatoDolutegravir Sodium/Lamivudine74$219,243
DescovyEmtricitabine/Tenofov Alafenam23$64,228
TivicayDolutegravir Sodium20$44,625
PrezcobixDarunavir/Cobicistat12$29,058
IsentressRaltegravir Potassium14$26,929
PifeltroDoravirine12$20,706
Vancomycin Hcl89$20,248
VemlidyTenofovir Alafenamide13$18,010
ErtapenemErtapenem Sodium24$16,577
CeftriaxoneCeftriaxone Sodium66$7,793
Cefepime Hcl17$6,238
Meropenem12$5,142
Ethambutol Hcl35$1,851
Rifampin38$1,443

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Vemlidy$1,640$408,480120 claims
Viiv Healthcare CompanyDovato, Tivicay$2,356$263,86894 claims
MerckIsentress, Pifeltro$808$47,63526 claims
Johnson & JohnsonPrezcobix$238$29,05812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Wilmington

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →